# Rohit Loomba

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/rohit-loomba/

## Facts

| Field | Value |
| --- | --- |
| Citations | 107,359 |
| Field | Liver Disease Diagnosis and Treatment |
| h-index | 157 |
| i10-index | 624 |
| Last Known Institution | University of San Diego |
| OpenAlex ID | https://openalex.org/A5052059601 |
| ORCID iD | https://orcid.org/0000-0002-4845-9991 |
| Works | 1,243 |

## Researcher papers

- [MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease](https://scholariq.org/papers/mafld-a-consensus-driven-proposed-nomenclature-for-metabolic-associated-fatty/)
- [A multisociety Delphi consensus statement on new fatty liver disease nomenclature](https://scholariq.org/papers/a-multisociety-delphi-consensus-statement-on-new-fatty-liver-disease/)
- [A multisociety Delphi consensus statement on new fatty liver disease nomenclature](https://scholariq.org/papers/a-multisociety-delphi-consensus-statement-on-new-fatty-liver-disease-3/)
- [Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030](https://scholariq.org/papers/modeling-nafld-disease-burden-in-china-france-germany-italy-japan-spain-united/)
- [A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis](https://scholariq.org/papers/a-phase-3-randomized-controlled-trial-of-resmetirom-in-nash-with-liver-fibrosis/)
- [Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial](https://scholariq.org/papers/obeticholic-acid-for-the-treatment-of-non-alcoholic-steatohepatitis-interim/)
- [Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19](https://scholariq.org/papers/association-of-inpatient-use-of-angiotensin-converting-enzyme-inhibitors-and/)
- [Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis](https://scholariq.org/papers/tirzepatide-for-metabolic-dysfunction-associated-steatohepatitis-with-liver/)
- [A multisociety Delphi consensus statement on new fatty liver disease nomenclature](https://scholariq.org/papers/a-multisociety-delphi-consensus-statement-on-new-fatty-liver-disease-2/)
- [Advancing the global public health agenda for NAFLD: a consensus statement](https://scholariq.org/papers/advancing-the-global-public-health-agenda-for-nafld-a-consensus-statement/)
- [A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH](https://scholariq.org/papers/a-randomized-controlled-trial-of-the-pan-ppar-agonist-lanifibranor-in-nash/)
- [Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis](https://scholariq.org/papers/magnetic-resonance-elastography-for-staging-liver-fibrosis-in-non-alcoholic/)

## Researcher topics

- [Liver Disease Diagnosis and Treatment](https://scholariq.org/topics/liver-disease-diagnosis-and-treatment/)
- [Liver Disease and Transplantation](https://scholariq.org/topics/liver-disease-and-transplantation/)
- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Liver Diseases and Immunity](https://scholariq.org/topics/liver-diseases-and-immunity/)
- [Diet, Metabolism, and Disease](https://scholariq.org/topics/diet-metabolism-and-disease/)

## Researcher university

- [University of San Diego](https://scholariq.org/institutions/university-of-san-diego/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.